Bleeding risk and safety profile related to the use of eptifibatide: a current review

Bibliography

• Chesebro JH, Knatterud G, Roberts R, Thrombolysis in myocardial infarction (TIMI) trial, phase i: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76(1):142-54
   PubMed Web of Science ®Google Scholar
• The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329(10):673-82
   PubMed Web of Science ®Google Scholar
• Rao SV, O'Grady K, Pieper KS, A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47(4):809-16
   PubMed Web of Science ®Google Scholar
• The Esprit Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356(9247):2037-44
   PubMed Web of Science ®Google Scholar
• Moscucci M, Fox KA, Cannon CP, Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J 2003;24(20):1815-23
   PubMed Web of Science ®Google Scholar
• Kinnaird TD, Stabile E, Mintz GS, Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92(8):930-5
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Harrington RA, Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289(7):853-63
   PubMed Web of Science ®Google Scholar
• Lee PY, Alexander KP, Hammill BG, Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286(6):708-13
   PubMed Web of Science ®Google Scholar
• The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336(24):1689-96
   PubMed Web of Science ®Google Scholar
• Doyle BJ, Rihal CS, Gastineau DA, Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009;53(22):2019-27
   PubMed Web of Science ®Google Scholar
• Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76(1):101-8
   PubMed Web of Science ®Google Scholar
• Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353(9148):227-31
   PubMed Web of Science ®Google Scholar
• Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979;64(5):1393-401
   PubMed Web of Science ®Google Scholar
• Mustard JF, Packham MA, Kinlough-Rathbone RL, Fibrinogen and ADP-induced platelet aggregation. Blood 1978;52(2):453-66
   PubMed Web of Science ®Google Scholar
• Phillips DR, Agin PP. Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis. J Biol Chem 1977;252(6):2121-6
   PubMed Web of Science ®Google Scholar
• Kohmura C, Gold HK, Yasuda T, A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb J Vasc Biol Am Heart Assoc 1993;13(12):1837-42
   PubMed Web of Science ®Google Scholar
• Scarborough RM. Development of eptifibatide. Am Heart J 1999;138(6 Pt 1):1093-104
   PubMed Web of Science ®Google Scholar
• Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat rev Drug Discov 2010;9(10):804-20
   PubMed Web of Science ®Google Scholar
• Qin J, Vinogradova O, Plow EF. Integrin bidirectional signaling: a molecular view. PLoS Biol 2004;2(6):e169
   PubMed Web of Science ®Google Scholar
• Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2(9):703-16
   PubMed Web of Science ®Google Scholar
• Plow EF, Haas TA, Zhang L, Ligand binding to integrins. J Biol Chem 2000;275(29):21785-8
   PubMed Web of Science ®Google Scholar
• D'Souza SE, Haas TA, Piotrowicz RS, Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell 1994;79(4):659-67
   PubMed Web of Science ®Google Scholar
• Scarborough RM, Rose JW, Hsu MA, Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J biol chem 1991;266(15):9359-62
   PubMed Web of Science ®Google Scholar
• Phillips DR, Teng W, Arfsten A, Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96(5):1488-94
   PubMed Web of Science ®Google Scholar
• The Impact II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349(9063):1422-8
   PubMed Web of Science ®Google Scholar
• Ohman EM, Kleiman NS, Gacioch G, Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95(4):846-54
   PubMed Web of Science ®Google Scholar
• Harrington RA, Kleiman NS, Kottke-Marchant K, Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76(17):1222-7
   PubMed Web of Science ®Google Scholar
• Tcheng JE, Harrington RA, Kottke-Marchant K, Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91(8):2151-7
   PubMed Web of Science ®Google Scholar
• Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94(9):2083-9
   PubMed Web of Science ®Google Scholar
• Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990;58(1):47-60
   PubMed Web of Science ®Google Scholar
• Gilchrist IC, O'Shea JC, Kosoglou T, Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104(4):406-11
   PubMed Web of Science ®Google Scholar
• O'Shea JC, Buller CE, Cantor WJ, Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287(5):618-21
   PubMed Web of Science ®Google Scholar
• Winchester DE, Wen X, Brearley WD, Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol 2011;57(10):1190-9
   PubMed Web of Science ®Google Scholar
• The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: receptor suppression using integrilin therapy. N Engl J Med 1998;339(7):436-43
   PubMed Web of Science ®Google Scholar
• Giugliano RP, White JA, Bode C, Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360(21):2176-90
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30
   PubMed Web of Science ®Google Scholar
• Gibson CM, Kirtane AJ, Murphy SA, Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006;152(4):668-75
   PubMed Web of Science ®Google Scholar
• Le May MR, Wells GA, Glover CA, Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc interv 2009;2(4):330-8
   PubMed Web of Science ®Google Scholar
• Brener SJ, Zeymer U, Adgey AA, Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39(3):377-86
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Roe MT, Harrington RA, Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 2003;41(8):1251-60
   PubMed Web of Science ®Google Scholar
• Carere RG, Webb JG, Buller CE, Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. Am Heart J 2000;139(1 Pt 1):52-8
   PubMed Web of Science ®Google Scholar
• Kiemeneij F, Laarman GJ, Odekerken D, A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol 1997;29(6):1269-75
   PubMed Web of Science ®Google Scholar
• Koch KT, Piek JJ, Prins MH, Triage of patients for short term observation after elective coronary angioplasty. Heart 2000;83(5):557-63
   PubMed Web of Science ®Google Scholar
• Ziakas AA, Klinke BP, Mildenberger CR, Safety of same-day-discharge radial percutaneous coronary intervention: a retrospective study. Am Heart J 2003;146(4):699-704
   PubMed Web of Science ®Google Scholar
• Fung AY, Saw J, Starovoytov A, Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 2009;53(10):837-45
   PubMed Web of Science ®Google Scholar
• Fischell TA, Attia T, Rane S, High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006;18(10):487-91
   PubMedGoogle Scholar
• Deibele AJ, Jennings LK, Tcheng JE, Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary eptifibatide (ICE) trial. Circulation2010;121(6):784-91
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Harrington RA, Rund MM, Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95(4):809-13
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Sane DC, Sigmon KN, Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32(2):311-19
   PubMed Web of Science ®Google Scholar
• Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97(3):426-9
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi M, Menozzi A, Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109(18):2203-6
   PubMed Web of Science ®Google Scholar
• George JN, Raskob GE, Shah SR, Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129(11):886-90
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998;54(9-10):701-6
   PubMed Web of Science ®Google Scholar
• Bougie DW, Wilker PR, Wuitschick ED, Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100(6):2071-6
   PubMed Web of Science ®Google Scholar
• Tcheng JE, Kereiakes DJ, Lincoff AM, Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104(8):870-5
   PubMed Web of Science ®Google Scholar
• Memon MA, Blankenship JC, Wood GC, Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000;109(3):213-17
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355(21):2203-16
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;133:e426-e579
   Google Scholar
• Tcheng JE, Lim IH, Srinivasan S, Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. Circ Cardiovasc Interv 2009;2(1):43-51
   PubMed Web of Science ®Google Scholar
• Marso SP, Amin AP, House JA, Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010;303(21):2156-64
   PubMed Web of Science ®Google Scholar